Difference between revisions of "Abnormal cannabidiol"
(Created page with "Abnormal cannabidiol (abn-cbd) is a synthetic regioisomer of cannabidiol, which unlike most other cannabinoids produces vasodilator effects, lowers blood pressure, and induces...") |
|||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
| − | Abnormal cannabidiol (abn-cbd) is a synthetic regioisomer of cannabidiol, which unlike most other cannabinoids produces vasodilator effects, lowers blood pressure, and induces cell migration, cell proliferation and mitogen-activated protein kinase activation in microglia, but without producing any psychoactive effects. It has been shown that the actions of abnormal cannabidiol are mediated through a site separate from the [[CB1]] and [[CB2 receptors]], which responds to abnormal cannabidiol, O-1602, and the endogenous ligands: anandamide (AEA), N-arachidonoyl glycine (NAGly) and N-arachidonoyl L-serine. Multiple lines of evidence support the proposed identification of this novel target in microglia as the previously "orphan" receptor GPR18. Another possible target of abnormal cannabidiol is GPR55, which has also received much attention as a putative [[cannabinoid receptor]], although a growing body of evidence points to lysophosphatidylinositol (LPI) as the endogenous ligand for GPR55. | + | Abnormal cannabidiol (abn-cbd) is a synthetic regioisomer of cannabidiol, which unlike most other cannabinoids produces vasodilator effects, lowers blood pressure, and induces cell migration, cell proliferation and mitogen-activated protein kinase activation in microglia, but without producing any psychoactive effects. It has been shown that the actions of abnormal cannabidiol are mediated through a site separate from the [[CB1]] and [[CB2 receptors]], which responds to abnormal cannabidiol, O-1602, and the endogenous ligands: anandamide (AEA), N-arachidonoyl glycine (NAGly) and N-arachidonoyl L-serine. Multiple lines of evidence support the proposed identification of this novel target in microglia as the previously "orphan" receptor GPR18. Another possible target of abnormal cannabidiol is GPR55, which has also received much attention as a putative [[cannabinoid receptor]], although a growing body of evidence points to lysophosphatidylinositol (LPI) as the endogenous ligand for GPR55.Further research suggests there are yet more additional cannabinoid receptors. |
| + | |||
| + | [[File:abnormal cannabidoil - Weed Depot.jpg|300px|thumb|left|Abnormal Cannabidiol]] | ||
Latest revision as of 09:18, 23 February 2015
Abnormal cannabidiol (abn-cbd) is a synthetic regioisomer of cannabidiol, which unlike most other cannabinoids produces vasodilator effects, lowers blood pressure, and induces cell migration, cell proliferation and mitogen-activated protein kinase activation in microglia, but without producing any psychoactive effects. It has been shown that the actions of abnormal cannabidiol are mediated through a site separate from the CB1 and CB2 receptors, which responds to abnormal cannabidiol, O-1602, and the endogenous ligands: anandamide (AEA), N-arachidonoyl glycine (NAGly) and N-arachidonoyl L-serine. Multiple lines of evidence support the proposed identification of this novel target in microglia as the previously "orphan" receptor GPR18. Another possible target of abnormal cannabidiol is GPR55, which has also received much attention as a putative cannabinoid receptor, although a growing body of evidence points to lysophosphatidylinositol (LPI) as the endogenous ligand for GPR55.Further research suggests there are yet more additional cannabinoid receptors.
